Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cordlife GroupSGX:P8A 41 Receivables Turnover is 0.33 as of Jun. 2026. GuruFocus rates SGX:P8A with a GF Score™ of 41/100 and a GF Value™ of S$0.14 (Fairly Valued). The stock has 4 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 91.58% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cordlife Group's Revenue for the
three
months ended in Jun. 2026 was S$8.30 Mil. Cordlife Group's average Accounts Receivable for the
three
months ended in Jun. 2026 was S$25.23 Mil.
Hence, Cordlife Group's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.33.
Cordlife Group (SGX:P8A) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cordlife Group Receivables Turnover Related Terms
Cordlife Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cordlife Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:P8A vs TMO, DHR, NTRA: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Cordlife Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cordlife Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cordlife Group (SGX:P8A) has a Receivables Turnover of 0.33 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cordlife Group and its competitors. According to the industry distribution chart, Cordlife Group ranks #185 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 91.6%.
Is Cordlife Group's Receivables Turnover too high?
Cordlife Group's current Receivables Turnover is 0.33. The Medical Diagnostics & Research industry median Receivables Turnover is 5.40. Cordlife Group's value of 0.33 is 93.9% below this industry median. Based on the distribution chart, Cordlife Group ranks #185 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Cordlife Group has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #185 out of 202 companies for Receivables Turnover. This places Cordlife Group in the lower half of its industry. The industry median Receivables Turnover is 5.40. Cordlife Group's value of 0.33 is 93.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.40, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current Receivables Turnover of 0.33 is 93.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current Receivables Turnover is 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (SGX:P8A) is currently considered Fairly Valued. The stock's GF Value™ is S$0.14, compared to a current price of S$0.13 — trading 5.7% below its estimated fair value. The current Receivables Turnover is 0.33 and 93.9% below the Medical Diagnostics & Research industry median of 5.40. Cordlife Group's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cordlife Group (SGX:P8A), the current Receivables Turnover is 0.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (SGX:P8A) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of S$0.13 is trading 5.7% below its estimated GF Value™ of S$0.14.
GuruFocus considers Cordlife Group to be Fairly Valued.
Key valuation signals for SGX:P8A:
Receivables Turnover: 0.33
GF Value™: S$0.14 vs. price of S$0.13 (5.7% below fair value)
Industry Position: 93.9% below the Medical Diagnostics & Research median (#185 of 202)
No single metric tells the full story. See the SGX:P8A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
41GF Score
Get the complete analysis for SGX:P8A
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:P8A has been successfully added to your 
